US Stock MarketDetailed Quotes
RNA Avidity Biosciences
- 43.330
- -0.470-1.07%
Close Nov 27 16:00 ET
- 43.340
- +0.010+0.02%
Post 20:01 ET
5.17BMarket Cap-15045P/E (TTM)
44.515High42.630Low730.13KVolume43.990Open43.800Pre Close31.64MTurnover0.79%Turnover RatioLossP/E (Static)119.31MShares56.00052wk High3.44P/B4.01BFloat Cap6.79052wk Low--Dividend TTM92.43MShs Float56.000Historical High--Div YieldTTM4.30%Amplitude4.825Historical Low43.330Avg Price1Lot Size
Avidity Biosciences Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -78.35%-65.62M | -30.51%-65M | -43.73%-70.38M | 12.63%-119.06M | 142.11%16.5M | -15.12%-36.79M | -40.12%-49.81M | -65.57%-48.97M | -43.72%-136.27M | -49.49%-39.19M |
| Net income from continuing operations | -53.55%-80.4M | -50.54%-70.79M | -31.42%-68.86M | -21.97%-212.22M | -19.76%-60.44M | -20.09%-52.36M | -2.92%-47.03M | -53.04%-52.39M | -47.44%-174M | -30.96%-50.47M |
| Depreciation and amortization | 25.44%710K | 29.87%687K | 63.94%641K | 51.48%2.1M | 61.42%615K | 52.97%566K | 64.29%529K | 24.52%391K | 117.06%1.39M | 83.17%381K |
| Other non cash items | 11.85%821K | 12.57%824K | 20.35%828K | 8.33%2.98M | 21.00%824K | 6.53%734K | 6.09%732K | -0.15%688K | 304.86%2.75M | --681K |
| Change In working capital | -18.99%6.01M | 61.91%-4.06M | -128.51%-10.34M | 764.99%61.13M | 1,756.06%68.9M | 109.76%7.41M | -515.44%-10.66M | -64.91%-4.53M | 52.21%7.07M | -45.51%3.71M |
| -Change in prepaid assets | -192.49%-4.82M | -34.36%-9.58M | -269.55%-2.53M | 47.94%-3.44M | 10.82%-3.01M | 274.09%5.21M | -489.99%-7.13M | 171.68%1.49M | -163.59%-6.62M | -207.32%-3.37M |
| -Change in payables and accrued expense | 189.56%14.09M | 683.93%8.5M | 1.47%-3.96M | -76.11%4.91M | -43.20%5.53M | -42.79%4.87M | -170.30%-1.46M | -1,659.30%-4.02M | 73.82%20.57M | 96.13%9.73M |
| -Change in other current liabilities | -14.06%-933K | -13.66%-932K | -14.60%-887K | -88.88%-3.33M | -20.53%-916K | -8.92%-818K | -226.69%-820K | ---774K | -652.99%-1.76M | ---760K |
| -Change in other working capital | -26.82%-2.34M | -63.99%-2.05M | -142.90%-2.96M | 1,330.21%62.99M | 3,671.92%67.3M | -49.76%-1.84M | -15.04%-1.25M | -32.21%-1.22M | -15.21%-5.12M | -77.90%-1.88M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -78.35%-65.62M | -30.51%-65M | -43.73%-70.38M | 12.63%-119.06M | 142.11%16.5M | -15.12%-36.79M | -40.12%-49.81M | -65.57%-48.97M | -43.72%-136.27M | -49.49%-39.19M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -1,432.49%-482.41M | -696.91%-274.87M | 83.27%-32.75M | 31.53%-130.07M | 757.05%51.04M | -387.95%-31.48M | 360.99%46.05M | -11.51%-195.68M | -130.20%-189.96M | 90.76%-7.77M |
| Net PPE purchase and sale | -84.62%-1.7M | 14.63%-531K | 49.73%-915K | -49.77%-4.23M | -1.53%-863K | -962.62%-923K | 52.95%-622K | -140.11%-1.82M | 24.52%-2.82M | 50.21%-850K |
| Net investment purchase and sale | -1,473.21%-480.71M | -687.81%-274.34M | 83.58%-31.83M | 32.75%-125.84M | 850.26%51.9M | -382.27%-30.56M | 385.94%46.67M | -10.96%-193.86M | -137.55%-187.13M | 91.60%-6.92M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -1,432.49%-482.41M | -696.91%-274.87M | 83.27%-32.75M | 31.53%-130.07M | 757.05%51.04M | -387.95%-31.48M | 360.99%46.05M | -11.51%-195.68M | -130.20%-189.96M | 90.76%-7.77M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 856,060.00%342.46M | 1,046.27%446.72M | 1,596.12%389.45M | -72.89%93.86M | -86.91%31.89M | -99.90%40K | 0.48%38.97M | -4.78%22.96M | 96.34%346.17M | 1,076.28%243.65M |
| Net common stock issuance | --465.15M | 1,036.43%433.05M | 988.37%244.24M | -82.44%60.55M | --0 | --0 | -0.46%38.11M | -6.90%22.44M | 97.38%344.78M | 2,577.96%243.08M |
| Net preferred stock issuance | ---- | ---- | ---- | --31.19M | ---- | ---- | ---- | ---- | --0 | ---- |
| Proceeds from stock option exercised by employees | 46,662.50%18.71M | -14,848.27%-127.72M | 27,823.85%145.2M | 52.80%2.13M | 21.70%701K | -86.80%40K | 72.17%866K | 5,100.00%520K | -15.07%1.39M | -50.56%576K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 856,060.00%342.46M | 1,046.27%446.72M | 1,596.12%389.45M | -72.89%93.86M | -86.91%31.89M | -99.90%40K | 0.48%38.97M | -4.78%22.96M | 96.34%346.17M | 1,076.28%243.65M |
| Net cash flow | ||||||||||
| Beginning cash position | 275.25%578.55M | 296.51%471.7M | -45.58%185.38M | 6.22%340.65M | -40.30%85.95M | 22.99%154.18M | -14.88%118.96M | 6.22%340.65M | -0.32%320.7M | -64.91%143.95M |
| Current changes in cash | -201.28%-205.56M | 203.43%106.85M | 229.15%286.32M | -878.37%-155.27M | -49.45%99.43M | -466.97%-68.23M | 344.44%35.21M | -22.52%-221.69M | 2,067.26%19.95M | 319.61%196.7M |
| End cash Position | 333.98%372.98M | 275.25%578.55M | 296.51%471.7M | -45.58%185.38M | -45.58%185.38M | -40.30%85.95M | 22.99%154.18M | -14.88%118.96M | 6.22%340.65M | 6.22%340.65M |
| Free cash flow | -78.50%-67.32M | -29.95%-65.54M | -40.38%-71.3M | 11.36%-123.29M | 139.06%15.64M | -18.40%-37.71M | -36.78%-50.43M | -67.44%-50.79M | -41.13%-139.09M | -43.40%-40.04M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data